Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Gynaecological cancers

4028 - TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: preliminary outcomes in cohort A.


20 Oct 2018


Poster Discussion session - Gynaecological cancers


Immunotherapy;  Cancer in Adolescents and Young Adults (AYA)

Tumour Site

Gestational Trophoblastic Neoplasia


Benoit You


B.M. You1, P.A. Bolze2, J. Lotz3, J. Massardier2, L. Gladieff4, T. Hajri2, D. Maucort-Boulch5, S. Bin6, A. Roux6, P. Rousset7, G. Freyer1, F. Golfier2

Author affiliations

  • 1 Citohl, Hospices Civiles de Lyon, 69002 - Lyon/FR
  • 2 Gynécologie, Centre De Référence Des Maladies Trophoblastiques, Institut de Cancérologie des Hospices Civils de Lyon, 69495 - Lyon/FR
  • 3 Medical Oncology, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 4 Oncologie Médicale, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 5 Biostatistics, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 6 Unité Recherche Et Epidémiologie Cliniques, Pôle de Santé Publique, LYON/FR
  • 7 Radiology, Institut de Cancérologie des Hospices Civils de Lyon, 69495 - Lyon/FR


Abstract 4028


In GTN patients resistant to chemotherapy, standard treatments include historic single agent or polychemotherapy regimens, known to be effective (65%-95% successful hCG normalization) and toxic. PD-L1 is constitutively expressed in all GTN subtypes (Bolze et al. Int J Gynecol Cancer 2017). The objective of TROPHIMMUN trial is to assess the efficacy of the anti-PD-L1 monoclonal antibody avelumab (Pfizer & Merck Serono) in patients with chemoresistant GTN.


In this multicenter trial (NCT03135769) activated in February 2017, avelumab is given at 10 mg/kg every 2 weeks in patients with GTN resistant to monochemotherapy (cohort A) or to polychemotherapy (cohort B). Avelumab is prescribed until hCG normalization, and for 3 additional cycles thereafter. The primary endpoint is the rate of patients with hCG normalization, following a 2 step Simon design. The outcomes of the intermediate efficacy analysis planned after enrollment of 6 cohort A patients are presented.


As of September 2018, 13 patients have been enrolled (27-47 years old, median: 33): 9 patients in cohort A; 4 patients in cohort B. Cohort A patients had: invasive moles (100%), stage I (78%) or stage III (22%); FIGO score 1-4 (56%) or 5-6 (44%) diseases; prior resistances to methotrexate (100%) & to actinomycine-D (11%). Among them, 7 patients (78%) experienced 62 adverse events: grade 1 (83.9%); grade 2 (14.5%, including 1 hypothyroidism); grade 3 (1 metrorragia disease-related). Among the first 6 patients assessed for planned intermediate analysis, 3 patients normalized hCG, and stopped treatment without any further sign of relapse (10.7 month follow-up). The other hCG declines observed in subsequently recruited patients are to be confirmed.


There is a strong rational for investigating immunotherapies in GTN patients. TROPHIMMUN trial preliminary outcomes suggest that avelumab might be effective, and better tolerated than standard chemotherapy in patients with resistance to single chemotherapy. This is the first clinical trial reporting potential cures with a non-chemotherapy agent in patients with this rare cancer.

Clinical trial identification


EudraCT Number: 2016-002322-37

Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.